⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9443405 | 0.74 | CRBN (0.35) | — | |
| SCHEMBL3763 | 0.70 | — | — | |
| SCHEMBL40761 | 0.70 | — | — | |
| SCHEMBL8377723 | 0.70 | — | — | |
| SCHEMBL27983204 | 0.70 | BRD4 (0.41) | — | |
| SCHEMBL422814 | 0.70 | — | — | |
| SCHEMBL8377755 | 0.70 | TYMP (0.32) | — | |
| SCHEMBL7650218 | 0.68 | TP53 (0.33) | — | |
| SCHEMBL29980142 | 0.68 | BRD4 (0.31) | — | |
| Water SCHEMBL28246131 | 0.68 | BRD4 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110540619-B | Modified urea-formaldehyde resin and preparation method thereof | 福建工程学院 | 2022-05-03 | — | — | CN | claimed |
| CN-117957245-A | T cell receptor recognizing C135Y, R H or M237I mutation in P53 | 美国政府(由卫生和人类服务部的部长所代表) | 2024-04-30 | — | — | CN | disclosed |
| CN-110603265-B | Compositions and methods for immunotherapy of cancer with anti-mesothelin | 莱蒂恩技术公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-117298260-A | Compositions and methods for treating cancer with DuoCAR | 莱蒂恩技术公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-111741757-B | Compositions and methods for treating cancer with anti-ROR 1 immunotherapy | 莱蒂恩技术公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-109843922-B | Compositions and methods for treating cancer with DuoCAR | 莱蒂恩技术公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-116829581-A | Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy | 莱蒂恩技术公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-116801898-A | Compositions and methods for treating cancer with anti-CD 19/CD22 immunotherapy | 莱蒂恩技术公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-116568823-A | Methods, systems, and apparatus for high throughput sequencing | 阿尔缇玛基因组学公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-116322734-A | HLA class II restricted DRB T cell receptor for RAS with G12D mutation | 美国卫生和人力服务部 | 2023-06-23 | — | — | CN | disclosed |
| CN-108368507-B | iRNA compositions of programmed cell death 1 ligand 1(PD-L1) and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2022-03-22 | — | — | CN | disclosed |